Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-05-23
2006-05-23
Housel, James C. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023700, C435S235100, C435S239000, C435S069100, C435S325000, C435S320100
Reexamination Certificate
active
07049428
ABSTRACT:
HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication.
REFERENCES:
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5077193 (1991-12-01), Mishiro et al.
patent: 5106726 (1992-04-01), Wang
patent: 5176994 (1993-01-01), Mishiro et al.
patent: 5218099 (1993-06-01), Reyes et al.
patent: 5298394 (1994-03-01), Arima et al.
patent: 5312737 (1994-05-01), Bolling et al.
patent: 5350671 (1994-09-01), Houghten et al.
patent: 5371017 (1994-12-01), Houghton et al.
patent: 5372928 (1994-12-01), Miyamura et al.
patent: 5378814 (1995-01-01), Houghton et al.
patent: 5389528 (1995-02-01), Houghton et al.
patent: 5427909 (1995-06-01), Okamoto et al.
patent: 5428145 (1995-06-01), Okamoto et al.
patent: 5436126 (1995-07-01), Wang
patent: 5443965 (1995-08-01), Reyes et al.
patent: 5527669 (1996-06-01), Resnick et al.
patent: 5538865 (1996-07-01), Reyes et al.
patent: 5550016 (1996-08-01), Okamoto
patent: 5552310 (1996-09-01), Yoshikura et al.
patent: 5576302 (1996-11-01), Cook et al.
patent: 5580718 (1996-12-01), Resnick et al.
patent: 5585258 (1996-12-01), Houghton et al.
patent: 5597691 (1997-01-01), Houghton et al.
patent: 5610054 (1997-03-01), Draper
patent: 5620843 (1997-04-01), Hellings et al.
patent: 5625034 (1997-04-01), Liao et al.
patent: 5625043 (1997-04-01), Priebe et al.
patent: 5641654 (1997-06-01), Maki et al.
patent: 5645983 (1997-07-01), Liao et al.
patent: 5654179 (1997-08-01), Lin
patent: 5656731 (1997-08-01), Urdea
patent: 5667992 (1997-09-01), Casey et al.
patent: 5670152 (1997-09-01), Weiner et al.
patent: 5670153 (1997-09-01), Weiner et al.
patent: 5677124 (1997-10-01), DuBois et al.
patent: 5679342 (1997-10-01), Houghton et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5698390 (1997-12-01), Houghton et al.
patent: 5712088 (1998-01-01), Houghton et al.
patent: 5714596 (1998-02-01), Houghton et al.
patent: 5837463 (1998-11-01), Tanaka et al.
patent: 5874565 (1999-02-01), Rice et al.
patent: 6153421 (2000-11-01), Yanagi et al.
patent: 6630343 (2003-10-01), Bartenschlager
patent: 0 318 216 (1989-05-01), None
patent: 0 388 232 (1990-09-01), None
patent: 0 510 952 (1992-10-01), None
patent: 0 521 318 (1993-01-01), None
patent: 0 645 451 (1995-03-01), None
patent: 2212511 (1989-07-01), None
patent: WO89/04669 (1989-06-01), None
patent: WO90/11089 (1990-10-01), None
patent: WO91/02820 (1991-03-01), None
patent: WO91/15771 (1991-10-01), None
patent: WO92/08734 (1992-05-01), None
patent: WO93/00365 (1993-01-01), None
patent: WO93/03186 (1993-02-01), None
patent: WO93/19183 (1993-09-01), None
patent: WO 95/20660 (1995-08-01), None
Gale et al., Virology 230(2):217-227, Apr. 1997.
Mizuno et al., Gastroenterology 109(6): 1933-40, Dec. 1995.
Verma et al., Nature, vol. 389, pp. 239-242 (1997).
Eck et al., “Gene-Based Therapy,” The Pharmacological Basis of Therapeutics, Goodman and Gilman, Eds., pp. 77-101(1996).
Orkin et al., “Report and Recommendation of the Panel to Assess the NIH Investment in Research o Gene Therapy”, NIH, (1995). online at www.nih.gov
ews/panelrep.html.
Houdebine, Journal of Biotechnology, vol. 34, pp. 269-287 (1994).
Landford et al., Virology, vol. 293 No. 1, pp. 1-9 (Feb. 2002).
Zhu et al., Journal of Virology, vol. 77 No. 17, pp. 9204-9210 (Sep. 2003).
Grobler et al., The Journal of Biological Chemistry, col. 278 No. 19, pp. 16741-16746 (May 2003).
Barton and Flanegan,J. Virol.67:822-831 (1993).
Blight and Gowans,Viral Hepatitis Rev.1:143-155 (1995).
Blight et al.,Amer. J. Path.143:1568-1573 (1993).
Boyer et al.,J. Hepatol.32(1 Suppl.) 98-112 (2000).
Bredenbeek et al.,J. Virol.67:6439-6446 (1993).
Brown et al.,Nucl. Acids Res.20:5041-5045 (1992).
Bukh et al.,Sem. Liver Dis.15:41-63 (1995).
Butkiewicz et al.,J. Virol.74, 4291-4301 (2000).
Chen et al.,Virology188:102-113 (1992).
Choo et al.,Science244:359-362 (1989).
Enomoto et al.,J. Hepatol.17:415-416 (1993).
Farci et al.,Science288:339-344 (2000).
Filocamo et al.,J. Virol.71:1417-1427 (1997).
Ghosh et al.,J. Biol. Chem.275:7184-7188 (2000).
Grakoui et al.,Proc. Natl. Acad. Sci. USA90:10583-10587 (1993).
Gunji et al.,Arch Virol.134:293-302 (1994).
Hahm et al.,Virology226:318-326 (1996).
Han et al.,Proc. Natl. Acad. Sci. USA88:1711-1715 (1991).
Hijikata et al.,J. Virol., 67, 1953-1958 (1993).
Honda et al.,J. Virol.73:4941-4951 (1999).
Houghton, pp. 1035-1058 In “Fields Virology” (B.N. Fields et al, Eds.), Ravin, New York.
Hutchison et al.,Proc. Nat'l. Acad. Sci. USA83:710 (1986).
Kolyhalov et al.,J. Virol.70:3363-3371 (1996).
Kolyhalov et al.,Science277:570 (1997).
Lemm and Rice,J. Virol.67:1905-1915 (1993).
Lemm et al., EMBO J. 13:2925-2934 (1994).
Lin et al.,J. Virol.68: 5063-5073 (1994).
Lohmann et al.,Science285:110-113 (1999).
Lu and Wimmer,Proc. Natl. Acad. Sci. USA93: 1412-1417 (1996).
Macejak et al.,Hepatology31:769-776 (2000).
Martell et al.,J. Virol.68: 3425-3436 (1994).
Mizutani et al.J. Virol, 70: 7219-7223 (1996).
Molla et al.,Nature356: 255-257 (1992).
Nakajima et al.,J. Virol.70:3325-3329 (1996).
Okamoto et al.,J. Gen. Virol.75:629-635 (1994).
Pileri et al.,Science282:938-941 (1998).
Purcell,Hepatology26:11S-14S (1997).
Rice et al.,J. Virol.61:3809-3819 (1987).
Rice et al.,New Biol.1:285-296 (1989).
Rice, pp. 931-960 In “Fields Virology” (1996, B.N. Fields et al., Eds.), Raven, New York (1996).
Shimotohno,Hepatol.21:887-8 (1995).
Tagawa,J. Gastroenterol. And Hepatol., 10:523-527 (1995).
Tanaka et al.,J. Virol.70:3307-3312 (1996).
Tanaka et al.,Biochem. Biophys. Res. Comm.215:744-749 (1996).
Trowbridge et al.,Arch Virol.143:501-511 (1998).
Wang et al.,J. Virol.67:3338-3344 (1993).
Yamada et al.,Virology223:255-261 (1996).
Yanagi et al.,Virology244:161-172 (1999).
Yanagi et al.,Virology262:250-263 (1999).
Yoo et al.,J. Virol.69:32-38 (1995).
Blight et al., “Efficient Initiation of HVC RNA Replication in Cell Culture”,Science, Dec. 8, 2000, vol. 290, pp. 1972-1974.
Frolov et al., J. Virol., vol. 72, Selection of RNA replicons capable of noncytopathic replication in mammalian cells: pp. 3854-3856; 1999.
Jansen et al., Virology, vol. 163, Complete nucleotide sequence of a cell culture-adapted variant of hepatitis A virus: comparison with wild-type virus with restricted capacity for in vitro replication, pp. 299-307, 1988.
Krieger et al., J. Virol., vol. 75, Enhancement of Hepatitis C Virus RNA replication by cell culture-adaptive mutations, pp. 4614-4624, 2001.
Lohmann et al., J. Virol., vol. 75, Mutations in Hepatitis C Virus RNAs conferring cell culture adaptation, pp. 1437-1449, 2001.
Lundkvist et al., J. of Virol., vol. 71, Cell culture adaptation of puumala hantavirus changes the Infectivity for its natural reservoir, Clethrionomys glareolus, and leads to accumulation of mutants with altered genomic RNA S segment, pp. 9515-9523, 1997.
Blight Keril J.
Rice, III Charles M.
Housel James C.
Lucas Zachariah
Thompson & Coburn LLP
Washington University
LandOfFree
HCV variants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HCV variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HCV variants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3570086